Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19998489 | 0.81 | LMNA (0.38) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL27251482 | 0.77 | POLB (0.52) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL17344748 | 0.74 | GABRA1 (0.45) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL12533397 | 0.74 | TRPA1 (0.33) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL28455887 | 0.74 | POLB (0.36) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL6406061 | 0.74 | LMNA (0.36) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL17914480 | 0.73 | LMNA (0.35) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL11128206 | 0.72 | POLB (0.44) | LMNAPOLBGAA | |
| SCHEMBL11421517 | 0.71 | GABRA1 (0.44) | LMNASLC6A2HTR2BGABRA1GABRB1 | |
| SCHEMBL17345135 | 0.71 | GAA (0.46) | LMNAADRA1APOLBGAAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150361093-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2015-12-17 | — | — | US | disclosed |
| US-20050085522-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-04-21 | — | — | US | disclosed |
| EP-1362038-A1 | NOVEL ALKYL PHENYLIMINO-IMIDAZOLIDINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-11-19 | — | — | EP | disclosed |
| US-20020169193-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG | 2002-11-14 | — | — | US | disclosed |
| WO-2002064570-A1 | NOVEL ALKYL PHENYLIMINO-IMIDAZOLIDINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361093-A1 | HIV REPLICATION INHIBITOR | RTF2, REV1, PCNA | TRPA1 4823/4885LMNA 3937/4885CHRM1 3605/4885 |
| US-20020169193-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | AGTR2, ADRB2, REN | TRPA1 4264/4885LMNA 2452/4885CHRM1 55/4885 |
| US-20050085522-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | AGTR2, F12, UTS2R | TRPA1 4240/4885LMNA 2420/4885CHRM1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.